Determination of doxazosin in different matrices: a review

  • Authors

    • Alankar Shrivastava Institute of Biomedical Education and Research, Mangalayatan University
    • Manali Jain
    • Rakhee Varshneya
    2014-07-30
    https://doi.org/10.14419/ijac.v2i2.3054

  • Abstract

    Doxazosin mesylate is used in the management of hypertension and benign prostatic hyperplasia. It is one of the important alpha one adrenoreceptor blocker. Alpha one adrenoreceptor blockers are most preferred therapy for symptomatic relief of benign prostatic hyperplasia. In this review analytical methods for the determination of doxazosin in different matrices are discussed. Analytical methods are classified in to spectrophotometry, chromatography and electroanalytical methods. This literature is also focused on advantages, disadvantages of different analytical methods. This review article is an attempt to provide information to the scientists engaged in research related to doxazosin.

    Keywords: Benign Prostatic Hyperplasia, Doxazosin Mesylate, Analytical Methods, Spectrophotometry, Chromatography, Electro analytical Methods.

  • References

    1. U.S. Department of Health and Human Services. (2006) Prostate Enlargement: Benign Prostatic Hyperplasia. National Institute of Diabetes and Digestive and Kidney Diseases. [Online] Available: http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/ProstateEnlargement_508.pdf.
    2. American Cancer Society. (2014) what is prostate cancer? Prostate Cancer: Early Detection. [Online] Available: http://www.cancer.org/cancer/prostatecancer/moreinformation/prostatecancerearlydetection/prostate-cancer-early-detection-what-is-prostate-cancer.
    3. Jon Kindblom. (2013) Role of prolactin in the prostate gland, studies in transgenic mouse models. 2003, Intellecta Docusys. [Online] Available: http://www.neurophys.gu.se/digitalAssets/1278/1278430_AVHANDLINGSRAM__Jon_Kindblom.pdf.
    4. Schauer I.G. and Rowley D.R., The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation, Volume 82, (2011) 200–210 http://dx.doi.org/10.1016/j.diff.2011.05.007.
    5. Freeman M.R., and Solomon K.R., Cholesterol and benign prostate disease. Differentiation, Volume 82, (2011) 244–252. http://dx.doi.org/10.1016/j.diff.2011.04.005.
    6. Shrivastava A., and Gupta V.B., Various treatment options for benign prostatic hyperplasia: A current update, J Mid-life Health 3, (2012), 10-9. http://dx.doi.org/10.4103/0976-7800.98811.
    7. Bechis S.K., Otsetov A.G., GeR Olumi A.F., Personalized Medicine for Management of Benign Prostatic Hyperplasia., J Urol, 2014, doi: 10.1016/j.juro.2014.01.114. http://dx.doi.org/10.1016/j.juro.2014.01.114.
    8. McLaren I.D., Jerde T.J., Bushman W., Role of interleukins, IGF and stem cells in BPH., Differentiation, Volume 82, (2011) 237–243. http://dx.doi.org/10.1016/j.diff.2011.06.001.
    9. Yamada S. and Ito Y., α1-Adrenoceptors in the Urinary Tract. Urinary Tract: Handbook of Experimental Pharmacology, K.E. Andersson and M.C. Michel, Ed. Springer Heidelberg Dordrecht London New York, Volume, 202. (2011).
    10. Irani J., Are all alpha-blockers created the same? Eur Urol, Volume 49, (2006), 420-2. http://dx.doi.org/10.1016/j.eururo.2005.12.032.
    11. Shrivastava A., Various Analytical Methods for the determi-nation of Terazosin in different matrices, World Journal of Analytical Chemistry, Volume 1(4), (2013) 80-86.
    12. Takahashi S. and Yamaguchi K., Satoru Sakura Clinical Study Group., Treatment of benign prostatic hyperplasia and aging: Impacts of alpha-1 blockers on sexual function. Journal of Men's Health, Volume 8(Suppl. 1), (2011) S25–S28. http://dx.doi.org/10.1016/S1875-6867 (11)60015-8.
    13. Perabo F.G.E. Drug development for LUTS - The challenge for industry. Drug Discovery Today: Therapeutic Strategies, Volume 9(1), (2012) e5–e14. http://dx.doi.org/10.1016/j.ddstr.2012.02.001.
    14. Shrivastava A., Patel A., Gupta, V.B., Stability Indicating HPTLC Determination of Terazosin in Tablet Formulation. World Journal of Analytical Chemistry, Volume 1(3), (2013) 31-36.
    15. Shrivastava A. and Aggrawal P., Various Analytical Meth-odologies for Determination of Selective α1A Receptor Blocker Tamsulosin Hydrochloride and its Combinations in different matrices. World Journal of Analytical Chemistry Volume 1(3), (2013) 37-48. doi: 10.12691/wjac-1-3-3.
    16. Ding H., Du W., Hou Z.Z., Wang H.Z., and Wang Z.P., Silo-dosin is effective for treatment of LUTS in men with BPH: a systematic review, Asian Journal of Andrology, Volume 15, (2013) 121-128. http://dx.doi.org/10.1038/aja.2012.102.
    17. A. Shrivastava, Benign Prostatic Hyperplasia: A Review of Different Treatment Options. In Handbook of Clinical Phar-macy. Editors: Fernández-Ginés FD, Nieto-Guindo P. OM-ICS Group eBooks, USA. (2014).
    18. Attia A.K., Abdel-Moety M.M., Abdel-Hamid S.G., Thermal analysis study of antihypertensive drug doxazosin mesilate., Arabian Journal of Chemistry, (2012) http://dx.doi.org/10.1016/j.arabjc.2012.08.006.
    19. Os I and Stokke H.P., Effects of doxazosin in the gastrointes-tinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. Journal of Cardiovascular Pharmacology, Volume 33, (1999) 791-797. http://dx.doi.org/10.1097/00005344-199905000-00017.
    20. Chou C.L., Current Medical Treatment for Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms. Incontinence & Pelvic Floor Dysfunction. Volume 1(Suppl 2), (2007), 15-19.
    21. Shorter D., Lindsay J.A., and Kosten T.R., The alpha-1 ad-renergic antagonist doxazosin for treatment of cocaine de-pendence: A pilot study, Drug and Alcohol Dependence, Volume 131(1–2), (2013) 66-70. http://dx.doi.org/10.1016/j.drugalcdep.2012.11.021.
    22. Erturhan, S., Bayrak, O., Sarica, K., Seckiner, I., Baturu, M. Sen H. Efficacy of medical expulsive treatment with doxazosin in pediatric patients. Urology, 81(3), (2013), 640-3. doi: 10.1016/j.urology.2012.11.031. http://dx.doi.org/10.1016/j.urology.2012.11.031.
    23. Wilt T.J., and MacDonald R., Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clin Interv Aging., Volume 1(4), (2006) 389-401. http://dx.doi.org/10.2147/ciia.2006.1.4.389.
    24. European Pharmacopoeia. 2007, European Directorate for the Quality of Medicines. Strasbourg.
    25. Thiyagarajan M., α-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia., International Journal of Experimental and Clinical Pharmacology, Volume 65, (2002) 119-128.
    26. Shrivastava A., and Gupta V.B., A Review on Various Ana-lytical Methods on Some Alpha Adrenergic Antagonists. Current Pharmaceutical Analysis, Volume 7, (2011) 27-41. http://dx.doi.org/10.2174/157341211794708695.
    27. Xu Q.A., and Madden T.L., Analytical Methods for Thera-peutic Drug Monitoring and Toxicology, John Wiley and Sons, New Jersey. (2011). http://dx.doi.org/10.1002/9780470909799.
    28. Humphreys J.E. and Waite M.A., Alpha-1 Blockers. A new generation of antihypertensive agents, Journal of Clinical Pharmacy and Therapeutics, Volume 14, (1989) 263-283. http://dx.doi.org/10.1111/j.1365-2710.1989.tb00248.x.
    29. Homma Y., Araki I, Igawa Y., Ozono S., Gotoh M., Yamanishi T., Yokoyama O., Yoshida M. and Japanese Soci-ety of Neurogenic Bladder, Clinical guideline for male lower urinary tract symptoms, International Journal of Urology, 16, (2009) 775–790. http://dx.doi.org/10.1111/j.1442-2042.2009.02369.x.
    30. Gurbuz M.C., Polat H., Canat L., Kilic M., and Caskurlu T., Efficacy of Three Different Alpha 1-Adrenergic Blockers and Hyoscine N-Butylbromide for Distal Ureteral Stones. Inter-national Brazilian Journal of Urology, Volume 37, (2011) 195-202.
    31. Chandran S., and Singh, R.S., Comparison of various interna-tional guidelines for analytical method validation. Pharmazie, 62, (2007) 4-14.
    32. Shrivastava A., and Gupta V.B., Methods for the determina-tion of limit of detection and limit of quantitation of the ana-lytical methods, Chron Young Sci Volume 2, (2011) 21-5. http://dx.doi.org/10.4103/2229-5186.79345.
    33. Araujo P., Key aspects of analytical method validation and linearity evaluation. Journal of Chromatography B Analytical Technology Biomedical Life Sciences, Volume 877, (2009) 2224-34.
    34. Kumar A., Kishore L., Kaur N., and Nair A., Method devel-opment and validation: Skills and tricks. Chron Young Sci., Volume 3, (2012) 3-11. http://dx.doi.org/10.4103/2229-5186.94303.
    35. Shrivastava A., and Saxena P., Validation of Analytical Methods: Methodology and Statistics. Ist edition, CBS Publi-cations, New Delhi. (2014).
    36. Marczenko Z., Balcerzak M., Separation, Preconcentration and Spectrophotometry in Inorganic Analysis. Elsevier Science Publishers, Netherlands. (2000).
    37. Ayad M.M., Abdellatef H.E., Hosny M.M., Sharaf Y.A., Spectrophotometric and spectrofluorimetric determination of amlodipine besilate and doxazosin mesilate in bulk and in dosage forms via Hantzsch reaction. International Journal of Pharmaceutical and Biomedical Research Volume 3(2), (2012), 111-116.
    38. Ammar R.A., EL-Brashy A.M., AL-Sahly T.N., Spectro-photometric and Spectrofluorometric Determination of Dox-azosin Mesylate in Tablets via Eosin Y, Asian Journal of Chemistry, Volume 26(1), (2014) 57-62.
    39. Nahata A., Spectrofluorimetry as an Analytical tool. Pharm Anal Acta, Volume 2, (2011) 107e. http://dx.doi.org/10.4172/2153-2435.1000107e.
    40. Shrivastava A., Saxena P., and Gupta V.B., Spectrophoto-metric estimation of tamsulosin hydrochloride by acid-dye method., Pharm Methods, Volume 2, (2011) 53-60. http://dx.doi.org/10.4103/2229-4708.81089.
    41. Altiokka G., Voltammetric determination of doxazosin in tablets using rotating platinum electrode. Journal of Pharma-ceutical and Biomedical Analysis, Volume 25, (2001) 387-391. http://dx.doi.org/10.1016/S0731-7085 (00)00515-X.
    42. Bebawy L.I., Moustafa A.A., Abo-Talib N.F., Stability-indicating methods for the determination of doxazosin mezylate and celecoxib. Journal of Pharmaceutical and Bio-medical Analysis, Volume 27(5), (2002) 779-93. http://dx.doi.org/10.1016/S0731-7085 (01)00523-4.
    43. El Sheikh, R., Esmail, N.S., Gouda, A.A., Basset, W.A., Extractive spectrophotometric determination of some α-adrenergic antagonists in pure forms and in pharmaceutical formulations. CI & CEQ, Volume 18(2), (2012) 179−191. http://dx.doi.org/10.2298/CICEQ110917060E.
    44. Aydoğmuş Z., Barla A., Spectrophotometric determination of doxazosin mesylate in tablets by ion-pair and charge-transfer complexation reactions, Journal of AOAC International, 92(1), (2009) 131-7.
    45. Sommer L., Analytical absorption spectrophotometry in the visible and ultraviolet, the principles. Elsevier Science Pub-lishers, Netherlands. (1989).
    46. Shrivastava A. and Gupta V.B. Ultra violet spectrophotomet-ric method: Not possible for the simultaneous estimation of alpha one adrenoreceptor blockers. Journal of Pharmaceutical Negative Results, Volume 2, (2011) 115-20. http://dx.doi.org/10.4103/0976-9234.90226.
    47. Shrivastava A. and Gupta V.B., HPLC: Isocratic or Gradient Elution and Assessment of Linearity in Analytical Methods, Journal of Advanced Scientific Research, Volume 3(2), (2012) 12-20.
    48. The Japanese Pharmacopoeia. Vth Edition. Second Supple-ment. The Ministry of Health, Labour and Welfare, 2007.
    49. Dhanya B., Suganthi A., Sen A.K., Sahoo U., and Seth A.K., Determination of Doxazosin Mesylate in Tablets by RP-HPLC., Indian Journal of Pharmaceutical Science, Volume 73(1), (2011) 115-120. http://dx.doi.org/10.4103/0250-474X.89772.
    50. Naidu N.V.S., Reddy M.R.M., and Suguna, P., Development and Validation of the HPLC Method for the Analysis of Doxazosin in Bulk Drug and Pharmaceutical Dosage Forms. International Journal of Pharmaceutical Science and Research 3(8), (2012) 2705-2711.
    51. Kulsum S., Vidya Sagar G., Padmalatha M., Sudheer P., and Bavandla S., Validated RP-HPLC method for the quantitation of doxazocin mesylate in bulk and pharmaceutical dosage forms. Asian Journal of Pharmaceutical Sciences and Clinical Research, Volume Volume 1(1), (2011) 1-5.
    52. Rao K.S., Deb K.B., Rao M.E.B., Patro S.S., and Patnaik A.K., Development and Validation of Stability Indicating Analytical Method for Doxazosin Mesylate and its Application to Kinetic Studies., Chemical Sciences Journal, Volume 3, (2012) 1-10.
    53. Basaveswara Rao, M.V., Prasanthi, V., Sivanadh, M., and Venkata Rao, G., Newer RP-HPLC method for the determi-nation of doxazosin in human plasma and formulation. Bulletin of Pharmaceutical Research, Volume 2(1), (2012) 1-4.
    54. Sreevatsav, S.K., Sunder. S.K, Maleraju, J., Racha, H., Ana-lytical method development and validation of doxazosin me-sylate uncoated tablets by RP-HPLC. International Journal of Biomedical Research, Volume 4(9), (2013) 465-476.
    55. Shrivastava A., and Gupta V.B., Validated HPLC and HPTLC Methods for Simultaneous Determination of Some α1-Adrenoreceptor Blockers. Latin American Journal of Pharmacy, Volume 31 (2), (2012) 279-86.
    56. Shrivastava A., and Gupta V.B., Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical For-mulations., Scientia Pharmaceutica, Volume 80, (2012) 619–631. http://dx.doi.org/10.3797/scipharm.1204-15.
    57. Vickrey T.M., Liquid Chromatography Detectors. Marcel Dekkar Inc, Newyork, Volume 23. (1983)
    58. Papadoyannis I.N., HPLC in clinical chemistry. Marcel Dek-kar. (1990)
    59. Dong M.W., Modern HPLC for Practicing Scientists. John Wiley and Sons, Inc Publications. (2006) http://dx.doi.org/10.1002/0471973106.
    60. Karch S.B., Postmortem Toxicology of Abused Drugs. CRC Press, USA. (2008)
    61. Schellinger A.P., and Carr P.W., Isocratic and gradient elution chromatography: a comparison in terms of speed, retention reproducibility and quantitation, Journal of Chromatography A., Volume 1109(2), (2006) 253-66. http://dx.doi.org/10.1016/j.chroma.2006.01.047.
    62. Swadesh J.K., HPLC: Practical and Industrial Applications, 2nd Edition. CRC Press, USA. (2001)
    63. Sripalakit P., Nermhom P., and Saraphanchotiwitthaya A., Improvement of Doxazosin Determination in Human Plasma Using High-Performance Liquid Chromatography with Fluo-rescence Detection, Journal of Chromatographic Science, Volume 43, (2005) 63-66. http://dx.doi.org/10.1093/chromsci/43.2.63.
    64. Bhavesh D., Pinal S., Saroj V., and Prakash, S., Determina-tion of doxazosin in human plasma by reverse phase high performance liquid chromatography with fluorescence detector, Indian Journal of Pharmaceutical Sciences, Volume 64(4), (2002) 354-356.
    65. Sripalakit P., Nermhom P., and Saraphanchotiwitthaya A., Validation and pharmacokinetic application of a method for determination of doxazosin in human plasma by high-performance liquid chromatography. Biomedical Chromatog-raphy, Volume 20(8), (2006) 729-35. http://dx.doi.org/10.1002/bmc.588.
    66. Wongsinsup C., Taesotikul W., Kaewvichit S., Sangsrijan S., and Sangsrijan S., Simple Method of Extraction and Deter-mination of Doxazosin Mesylate in Human Plasma by High – Performance Liquid Chromatography with Fluorescence De-tector. CMU. Journal of Natural Science, Volume 6(2), (2007) 231-240.
    67. Kwon Y.H., Gwak H.S., Yoon S.J., and Chun I.K., Pharma-cokinetics of Doxazosin Gastrointestinal Therapeutic System after Multiple Administration in Korean Healthy Volunteers., Drug Development and Industrial Pharmacy, Volume 33(8), (2007) 824-829. http://dx.doi.org/10.1080/03639040601012999.
    68. Kaewvichit S., Thongsawat S., Taesotikul W., Wongsinsup C., and Yotsawimonwat S., Duangrat, C., et al., Bioequivalence study of doxazosin tablets in healthy thai male volunteers. Thai Journal of Pharmacology, Volume 29(2), (2007) 19-24.
    69. Cubbon S., Antonio C., Wilson J., and Thomas-Oates J., Metabolomic applications of HILIC-LC-MS. Mass Spec-trometry Reviews, Volume 29(5), (2010) 671-84. http://dx.doi.org/10.1002/mas.20252.
    70. Zhang W., Han F., Zhao H., Lin Z.J., Huang, Q.M., and Weng, N., Determination of metformin in rat plasma by HILIC-MS/MS combined with Tecan automation and direct injection. Biomedical Chromatography, Volume 26(10), (2012) 1163-9. http://dx.doi.org/10.1002/bmc.2673.
    71. Ji H.Y., Park E.J., Lee K.C., Lee H.S., Quantification of dox-azosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. Journal of Separation Science, Volume 31(9), (2008) 1628-33. doi: 10.1002/jssc.200700662. http://dx.doi.org/10.1002/jssc.200700662.
    72. Ardrey R.E., Liquid Chromatography - Mass Spectrometry: An Introduction. John Wiley and Sons, England, (2003) http://dx.doi.org/10.1002/0470867299.
    73. Chytil L., Strauch B., Cvačka J., Marešová V., Widimský J., Jr, Holaj R et al., Determination of doxazosin and verapamil in human serum by fast LC–MS/MS: Application to document non-compliance of patients. Journal of Chromatography B, 878, (2010) 3167–3173. http://dx.doi.org/10.1016/j.jchromb.2010.09.032.
    74. Erceg M., Cindric M., Frketic L.P., Vertzoni M., Cetina-Cižmek B., Reppas C., A LC–MS–MS Method for Determi-nation of Low Doxazosin Concentrations in Plasma after Oral Administration to Dogs, Journal of Chromatography Science, Volume 48, (2010) 114-119. http://dx.doi.org/10.1093/chromsci/48.2.114.
    75. Chen S., and Kord A., UPLC method development. Editor: Q. Alan Xu. First Edition, In Ultra-High Performance Liquid Chromatography and its Applications, John Wiley and Sons, Inc. (2013)http://dx.doi.org/10.1002/9781118533956.ch1.
    76. Al-Dirbashi O.Y., Aboul-Enein H.Y., Jacob M., Al-Qahtani K., and Rashed M.S., UPLC-MS/MS determination of dox-azosine in human plasma. Analytical and Bioanalytical Chemistry, 385, (2006) 1439-1443. http://dx.doi.org/10.1007/s00216-006-0553-8.
    77. Srivastava MM. HPTLC, Springer. (2011).
    78. Andol H.C., and Purohit V.K., High Performance Thin Layer Chromatography (HPTLC): A Modern Analytical tool for Biological Analysis. Nature and Science, Volume 8(10), (2010), 58-61.
    79. Shepherd R.W., Bunting P.S., Khan M., Hill J.G., Soldin S.J., Gall D.G., A rapid, sensitive method for accurate analysis of individual bile acids in biological fluids by high performance thin-layer chromatography and densitometry., Clinical Bio-chemistry, Volume 11(3), (1978) 106-11. http://dx.doi.org/10.1016/S0009-9120 (78)90112-1.
    80. Sane R.T., Francis M., Hijli P.S., Pawar S., Arvind R.P. De-termination of doxazosin in its pharmaceutical formulation by high-performance thin-layer chromatography. Journal of Planar Chromatography 15, (2002) 34-7. http://dx.doi.org/10.1556/JPC.15.2002.1.6.
    81. Shrivastava A., Analytical methods for venlaflaxine hydro-chloride and metabolites determinations in different matrices. Systemic Reviews in Pharmacy, Volume 3, (2012), 42-50. http://dx.doi.org/10.4103/0975-8453.107141.
    82. Shrivastava A., Sharma J., and Soni V., Various electroana-lytical methods for the determination of uranium in different matrices, Bulletin of Faculty of Pharmacy, Cairo University., 51(1), (2013) 113–129. http://dx.doi.org/10.1016/j.bfopcu.2012.09.003.
    83. Zuman P., Principles of applications of polarography and voltammetry in the analysis of drugs. FABAD Journal of Pharmaceutical Science, 31, (2006) 97–115.
    84. Arranz A., Moreda J.M., and Arranz J.F., Preconcentration and Voltammetric Determination of the Antihypertensive Doxazosin on a C8 Modified Carbon Paste Electrode. Micro-chimica Acta., Volume 134(1-2), (2000) 69-75. http://dx.doi.org/10.1007/s006040070056.
    85. Altiokka G., and Tuncel M., Pulse polarographic (constant and increasing) determinations doxazosin in pharmaceutical tablets, Journal of Pharmaceutical and Biomedical Analysis, Volume 17, (1998) 169–175. http://dx.doi.org/10.1016/S0731-7085 (97)00211-2.
    86. Arranz A., de Betono S.F., Moreda J.M., Cid A., Arranz J.F., Cathodic Stripping Voltammetric Determination of Doxazosin in Urine and Pharmaceutical Tablets Using Carbon Paste Electrodes. Analyst, Volume 122, (1997) 849–854. http://dx.doi.org/10.1039/a701210a.
    87. Rani M.E., Doxazosin dosage form in tablets by Cerimetric method. World J Pharmaceutical Research. Volume 3(2), (2014) 2280-2286.
    88. Walb T.A., and James A.E., Permanganate and cerimetric methods in pharmaceutical assays. A study of the relative merits. Journal of the American Pharmaceutical Association, Volume 29(5), (1940) 221–224. http://dx.doi.org/10.1002/jps.3030290508.
    89. Rozet E., Ziemons E., Marini R.D., Boulange, B., and Hubert P., Validation of analytical methods involved in dissolution assays: Acceptance limits and decision methodologies, Ana-lytica Chimica Acta, 751, (2012) 44–51. http://dx.doi.org/10.1016/j.aca.2012.09.017.

  • Downloads

  • How to Cite

    Shrivastava, A., Jain, M., & Varshneya, R. (2014). Determination of doxazosin in different matrices: a review. International Journal of Advanced Chemistry, 2(2), 109-116. https://doi.org/10.14419/ijac.v2i2.3054

    Received date: 2014-06-19

    Accepted date: 2014-07-26

    Published date: 2014-07-30